Loading clinical trials...
Loading clinical trials...
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Proof of Concept Study of the Efficacy and Safety of Fremanezumab for Treatment of Patients With Fibromyalgia
Conditions
Interventions
Fremanezumab
Placebo
Locations
49
United States
Teva Investigational Site 14159
Birmingham, Alabama, United States
Teva Investigational Site 14174
Huntsville, Alabama, United States
Teva Investigational Site 14431
Mesa, Arizona, United States
Teva Investigational Site 14166
Oceanside, California, United States
Teva Investigational Site 14435
Panorama City, California, United States
Teva Investigational Site 14168
Sacramento, California, United States
Start Date
July 31, 2019
Primary Completion Date
January 19, 2022
Completion Date
January 19, 2022
Last Updated
March 30, 2023
NCT05901259
NCT03759522
NCT07186751
NCT06574165
NCT06157866
NCT05067998
Lead Sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions